臓器移植診断の世界市場 (2023-2033年)：提供区分・用途・技術・移植タイプ・エンドユーザー・地域/国別の分析・予測

世界の臓器移植診断の市場規模は、2022年の40億3,000万米ドルから、予測期間中は10.45%のCAGRで推移し、2033年には117億8,000万米ドルの規模に成長すると予測されています。

同市場の成長の主な要因としては、臓器不全に至る慢性疾患の増加、幹細胞治療の導入の拡大、白血病の発症率の増加、移植診断における高度な分子・ゲノム技術開発のメリット、償還スキームを含む有利な法規制シナリオの存在などが挙げられます。

当レポートでは、世界の臓器移植診断の市場を調査し、市場シナリオ、法規制・償還環境、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 製品の定義

第2章 市場の範囲

第3章 調査手法

第4章 世界の臓器移植診断市場：概要

• 現在の市場シナリオ
• 市場フットプリント
• COVID-19による市場への影響

第5章 世界の臓器移植診断市場：産業分析

• 概要
• 米国の法的要件と規制の枠組み
• 欧州の法的要件と枠組み
• アジア太平洋における法的要件と枠組み
• 償還シナリオ
• 特許分析

第6章 世界の臓器移植診断市場：市場力学

• 影響分析
• 市場促進要因
• 市場抑制要因
• 市場機会

第7章 競合の考察

• 概要
• 主要な戦略・展開
• 市場シェア分析
• 成長シェア分析

第8章 世界の臓器移植診断市場：提供区分別

• 概要
• 製品
  • キット・アッセイ
  • 消耗品
• サービス

第9章 世界の臓器移植診断市場：移植タイプ別

• 概要
• 固形臓器移植
  • 腎臓
  • 肝臓
  • 肺
  • 膵臓
  • その他
• 幹細胞移植

第10章 世界の臓器移植診断市場：用途別

• 概要
• 診断
  • ドナー検査
  • レシピエント検査
• トランスレーショナルリサーチ

第11章 世界の臓器移植診断市場：技術別

• 概要
• 分子技術
  • PCR
  • サンガーシーケンシング
  • 次世代シーケンシング（NGS）
  • その他シーケンシング
• 非分子技術
  • 血清学
  • フローサイトメトリー
• その他

第12章 世界の臓器移植診断市場：エンドユーザー別

• 概要
• 病院・移植センター
• 学術研究機関
• リファレンスラボ
• その他

第13章 地域

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• その他の地域

第14章 企業プロファイル

• 製造業者
• サービスプロバイダー

List of Figures

• Figure 1: Global Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 2: Global Organ Transplant Diagnostics Market, Impact Analysis
• Figure 3: Global Organ Transplant Diagnostics Market (by Offering), Share (%), 2022 and 2033
• Figure 4: Global Organ Transplant Diagnostics Market (by Transplant Type), Share (%), 2022 and 2033
• Figure 5: Global Organ Transplant Diagnostics Market (by Application), Share (%), 2022 and 2033
• Figure 6: Global Organ Transplant Diagnostics Market (by Technology), Share (%), 2022 and 2033
• Figure 7: Global Organ Transplant Diagnostics Market (by End User), Share (%), 2022 and 2033
• Figure 8: Global Organ Transplant Diagnostics Market (by Region), $Billion, 2022 and 2033
• Figure 9: Global Organ Transplant Diagnostics Market Segmentation
• Figure 10: Global Organ Transplant Diagnostics Market: Research Methodology
• Figure 11: Primary Research Methodology
• Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 13: Top-Down Approach (Segment-Wise Analysis)
• Figure 14: Global Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 15: Global Organ Transplant Diagnostics Market, Patent Analysis (by Country), January 2018-December 2022
• Figure 16: Global Organ Transplant Diagnostics Market, Patent Analysis (by Year), January 2018-December 2022
• Figure 17: Global Organ Transplant Diagnostics Market, Impact Analysis
• Figure 18: New Liver Cirrhosis and Other Chronic Liver Diseases Cases, Thousand, 2017 and 2021
• Figure 19: Global Number of Solid Organ Transplants, 2017-2021
• Figure 20: Applications of Stem Cell Therapy
• Figure 21: Number of Transplants Performed and Patients on the Waiting List (by Organ), 2022
• Figure 22: Global Organ Transplant Diagnostics Market, Total Number of Key Developments, January 2018-April 2023
• Figure 23: Synergistic Activities, January 2018-April 2023
• Figure 24: Product and Service Launches, January 2018-April 2023
• Figure 25: Product Approvals, January 2018-April 2023
• Figure 26: Acquisitions and Mergers, January 2018-April 2023
• Figure 27: Regulatory Accreditions, January 2018-April 2023
• Figure 28: Global Organ Transplant Diagnostics Market, Market Share Analysis, %, 2021 and 2022
• Figure 29: Global Organ Transplant Diagnostics Market, Growth-Share Matrix (by Company), 2022
• Figure 30: Global Organ Transplant Diagnostics Market (by Offering)
• Figure 31: Global Organ Transplant Diagnostics Market (Products), $Billion, 2022-2033
• Figure 32: Global Organ Transplant Diagnostics Market (Kits and Assays), $Million, 2022-2033
• Figure 33: Global Organ Transplant Diagnostics Market (Consumables), $Million, 2022-2033
• Figure 34: Global Organ Transplant Diagnostics Market (Services), $Billion, 2022-2033
• Figure 35: Global Organ Transplant Diagnostics Market (by Transplant Type)
• Figure 36: Global Organ Transplant Diagnostics Market (Solid Organ Transplant), $Billion, 2022-2033
• Figure 37: Global Organ Transplant Diagnostics Market (Kidney), $Billion, 2022-2033
• Figure 38: Global Organ Transplant Diagnostics Market (Liver), $Million, 2022-2033
• Figure 39: Global Organ Transplant Diagnostics Market (Lung), $Million, 2022-2033
• Figure 40: Global Organ Transplant Diagnostics Market (Pancreas), $Million, 2022-2033
• Figure 41: Global Organ Transplant Diagnostics Market (Other Organs Transplant), $Million, 2022-2033
• Figure 42: Global Organ Transplant Diagnostics Market (Stem Cell Transplant), $Billion, 2022-2033
• Figure 43: Global Organ Transplant Diagnostics Market (by Application)
• Figure 44: Global Organ Transplant Diagnostics Market (Diagnostics), $Billion, 2022-2033
• Figure 45: Global Organ Transplant Diagnostics Market (Donor Testing), $Billion, 2022-2033
• Figure 46: Global Organ Transplant Diagnostics Market (Pre-Transplantation Testing), $Million, 2022-2033
• Figure 47: Global Organ Transplant Diagnostics Market (Histocompatibility Testing), $Million, 2022-2033
• Figure 48: Global Organ Transplant Diagnostics Market (Blood Profiling Testing), $Million, 2022-2033
• Figure 49: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
• Figure 50: Global Organ Transplant Diagnostics Market (Post-Transplantation Testing), $Million, 2022-2033
• Figure 51: Global Organ Transplant Diagnostics Market (Post-Infection Testing), $Million, 2022-2033
• Figure 52: Global Organ Transplant Diagnostics Market (Risk of Disorder Testing), $Million, 2022-2033
• Figure 53: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
• Figure 54: Global Organ Transplant Diagnostics Market (Recipient Testing), $Billion, 2022-2033
• Figure 55: Global Organ Transplant Diagnostics Market (Pre-Transplantation Testing), $Million, 2022-2033
• Figure 56: Global Organ Transplant Diagnostics Market (Histocompatibility Testing), $Million, 2022-2033
• Figure 57: Global Organ Transplant Diagnostics Market (Blood Profiling Testing), $Million, 2022-2033
• Figure 58: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
• Figure 59: Global Organ Transplant Diagnostics Market (Post-Transplantation Testing), $Billion, 2022-2033
• Figure 60: Global Organ Transplant Diagnostics Market (Post-Infection Testing), $Million, 2022-2033
• Figure 61: Global Organ Transplant Diagnostics Market (Risk of Disorder Testing), $Million, 2022-2033
• Figure 62: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
• Figure 63: Global Organ Transplant Diagnostics Market (Translational Research), $Million, 2022-2033
• Figure 64: Global Organ Transplant Diagnostics Market (by Technology)
• Figure 65: Global Organ Transplant Diagnostics Market (Molecular Technologies), $Billion, 2022-2033
• Figure 66: Global Organ Transplant Diagnostics Market (PCR), $Million, 2022-2033
• Figure 67: Global Organ Transplant Diagnostics Market (Sanger Sequencing), $Million, 2022-2033
• Figure 68: Global Organ Transplant Diagnostics Market (Next-Generation Sequencing), $Million, 2022-2033
• Figure 69: Global Organ Transplant Diagnostics Market (Other Molecular Technologies), $Million, 2022-2033
• Figure 70: Global Organ Transplant Diagnostics Market (Non-Molecular Technologies), $Billion, 2022-2033
• Figure 71: Global Organ Transplant Diagnostics Market (Serology), $Billion, 2022-2033
• Figure 72: Global Organ Transplant Diagnostics Market (Flow Cytometry), $Million, 2022-2033
• Figure 73: Global Organ Transplant Diagnostics Market (Other Technologies), $Million, 2022-2033
• Figure 74: Global Organ Transplant Diagnostics Market (by End User)
• Figure 75: Global Organ Transplant Diagnostics Market (Hospitals and Transplant Centers), $Billion, 2022-2033
• Figure 76: Global Organ Transplant Diagnostics Market (Academic and Research Institutions), $Billion, 2022-2033
• Figure 77: Global Organ Transplant Diagnostics Market (Reference Laboratories), $Million, 2022-2033
• Figure 78: Global Organ Transplant Diagnostics Market (Other End Users), $Million, 2022-2033
• Figure 79: Global Organ Transplant Diagnostics Market Share and CAGR (by Region), 2022 and 2023-2033
• Figure 80: North America Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 81: North America Organ Transplant Diagnostics Market (by Country), Share (%), 2023 and 2033
• Figure 82: U.S. Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 83: Canada Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 84: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 85: Europe Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
• Figure 86: France Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 87: Spain Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 88: U.K. Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 89: Italy Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 90: Germany Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 91: Switzerland Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 92: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 93: Asia-Pacific Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 94: Asia-Pacific Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
• Figure 95: China Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 96: India Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 97: South Korea Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 98: Japan Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 99: Australia Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 100: Singapore Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 101: Rest-of-Asia-Pacific Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 102: Latin America Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 103: Latin America Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
• Figure 104: Brazil Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 105: Mexico Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 106: Rest-of-Latin America Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 107: Rest-of-the-World Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 108: Total Number of Companies Profiled
• Figure 109: Global Organ Transplant Diagnostics Market Overview, Key Companies
• Figure 110: Abbott Laboratories: Product Portfolio
• Figure 111: Abbott Laboratories: Overall Financials, $Billion, 2020-2022
• Figure 112: Abbott Laboratories: Net Revenue (by Business Segment), $Billion, 2020-2022
• Figure 113: Abbott Laboratories: Net Revenue (by Region), $Billion, 2020-2022
• Figure 114: Abbott Laboratories: R&D Expenditure, $Billion, 2020-2022
• Figure 115: BAG Group GmbH: Overall Product Portfolio
• Figure 116: bioMerieux S.A.: Overall Product Portfolio
• Figure 117: bioMerieux S.A.: Overall Financials, $Million, 2019-2021
• Figure 118: bioMerieux S.A.: Net Revenue (by Region), $Million, 2019-2021
• Figure 119: bioMerieux S.A.: R&D Expenditure, $Million, 2019-2021
• Figure 120: Bio-Rad Laboratories, Inc.: Product Portfolio
• Figure 121: Bio-Rad Laboratories, Inc.: Overall Financials, $Billion, 2020-2022
• Figure 122: Bio-Rad Laboratories, Inc.: Net Revenue (by Business Segment), $Million, 2020-2022
• Figure 123: Bio-Rad Laboratories, Inc.: Net Revenue (by Region), $Million, 2020-2022
• Figure 124: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 125: Eurobio Scientific (Genome Diagnostics B.V.): Overall Product Portfolio
• Figure 126: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
• Figure 127: F. Hoffmann-La Roche Ltd.: Overall Financials, $Billion, 2020-2022
• Figure 128: F. Hoffmann-La Roche Ltd.: Net Revenue (by Business Segment), $Billion, 2020-2022
• Figure 129: F. Hoffmann-La Roche Ltd.: Diagnostics Revenue (by Region), $Billion, 2020-2022
• Figure 130: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Billion, 2020-2022
• Figure 131: Illumina, Inc.: Overall Product Portfolio
• Figure 132: Illumina, Inc.: Overall Financials, $Million, 2020-2022
• Figure 133: Illumina, Inc.: Net Revenue (by Business Segment), $Million, 2020-2022
• Figure 134: Illumina, Inc.: Net Revenue (by Region), $Million, 2020-2022
• Figure 135: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 136: Immucor, Inc.: Product Portfolio
• Figure 137: Omixon Inc.: Overall Product Portfolio
• Figure 138: QIAGEN N.V.: Product Portfolio
• Figure 139: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
• Figure 140: QIAGEN N.V.: Net Revenue (by Business Segment), $Million, 2019-2021
• Figure 141: QIAGEN N.V.: Net Revenue (by Region), $Million, 2019-2021
• Figure 142: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
• Figure 143: Thermo Fisher Scientific Inc.: Product Portfolio
• Figure 144: Thermo Fisher Scientific Inc.: Overall Financials, $Billion, 2020-2022
• Figure 145: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), $Billion, 2020-2022
• Figure 146: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Billion,2020-2022
• Figure 147: Thermo Fisher Scientific Inc.: R&D Expenditure, $Billion, 2020-2022
• Figure 148: ARUP Laboratories: Overall Product Portfolio
• Figure 149: CareDx, Inc.: Overall Product Portfolio
• Figure 150: CareDx, Inc.: Overall Financials, $Million, 2020-2022
• Figure 151: CareDx, Inc.: Net Revenue (by Business Segment), $Million, 2020-2022
• Figure 152: CareDx, Inc.: Net Revenue (by Region), $Million, 2020-2022
• Figure 153: CareDx, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 154: Laboratory Corporation of America Holdings: Overall Product Portfolio
• Figure 155: Laboratory Corporation of America Holdings: Overall Financials, $Billion, 2020-2022
• Figure 156: Laboratory Corporation of America Holdings: Net Revenue (by Business Segment), $Billion, 2020-2022
• Figure 157: Quest Diagnostics Incorporated: Product Portfolio
• Figure 158: Quest Diagnostics Incorporated: Overall Financials, $Billion, 2020-2022
• Figure 159: Quest Diagnostics Incorporated: Net Revenue (by Business Segment), $Billion, 2020-2022

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Key Coverage Providers for Organ Transplant Diagnostics Tests
• Table 3: North America Organ Transplant Diagnostics Market, Impact Analysis
• Table 4: North America Organ Transplant Test Volume, by Transplant Type, 2021
• Table 5: Europe Organ Transplant Diagnostics Market, Impact Analysis
• Table 6: Europe Organ Transplant Test Volume, by Transplant Type, 2021
• Table 7: Asia-Pacific Organ Transplant Diagnostics Market, Impact Analysis
• Table 8: Asia-Pacific Organ Transplant Test Volume, by Transplant Type, 2021
• Table 9: Latin America Organ Transplant Diagnostics Market, Impact Analysis
• Table 10: Latin America Organ Transplant Test Volume, by Transplant Type, 2021
• Table 11: Rest-of-the-World Organ Transplant Diagnostics Market, Impact Analysis
• Table 12: Rest-of-the-World Organ Transplant Test Volume, by Transplant Type, 2021

Global Organ Transplant Diagnostics Market to Reach $11.78 Billion by 2033

Global Organ Transplant Diagnostics Market: Industry Overview

In 2022, the global organ transplant diagnostics market was valued at $4.03 billion and is expected to reach $11.78 billion by 2033, with a CAGR of 10.45% during the forecast period 2023-2033. The key factors driving growth include a rise in the incidence of chronic diseases leading to organ failure increases in the use of transplant diagnostics, increase in the adoption of stem cell therapy and incidences of leukemia leading to an upsurge in demand for transplant diagnostics tests, advantages of developing advanced molecular and genomic technologies in the transplant diagnostics, and presence of favorable regulatory scenario including reimbursement schemes.

Market Lifecycle Stage

The global organ transplant diagnostics market is in the developed phase. The development of non-invasive techniques for monitoring transplant recipients using NGS and advancements in human leukocyte antigen (HLA) typing tests for an organ transplant are some of the major opportunities in the global organ transplant diagnostics market.

Impact of COVID-19

The COVID-19 pandemic impacted the healthcare segment in different ways. The organ transplant segment of the industry got highly impacted by the pandemic, as the focus of hospitals and ambulatory centers shifted toward the affected patients. Moreover, as a method of prevention, surgeries got delayed, which had a significant effect on organ transplant procedures and on organ transplant diagnostics tests.

Market Segmentation:

Segmentation 1: by Offering

• Products
• Services

The global organ transplant diagnostics market (by offering) is expected to be dominated by the services segment.

Segmentation 2: by Transplant Type

• Solid Organ Transplant
• Stem Cell Transplant

The global organ transplant diagnostics market (by transplant type) is expected to be dominated by the solid organ transplant segment.

Segmentation 3: by Application

• Diagnostics
• Translational Research

The global organ transplant diagnostics market (by application) is expected to be dominated by the diagnostics segment.

Segmentation 4: by Technology

• Molecular Technologies
• Non-Molecular Technologies
• Other Technologies

The global organ transplant diagnostics market (by technology) is expected to be dominated by the molecular technologies segment.

Segmentation 5: by End User

• Hospitals and Transplant Centers
• Academic and Research Institutions
• Reference Laboratories
• Other End Users

The global organ transplant diagnostics market (by end user) is expected to be dominated by the hospitals and transplant centers segment.

Segmentation 6: by Region

• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, Switzerland, and Rest-of-Europe
• Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

The global organ transplant diagnostics market (by region) is dominated by the North America region.

Recent Developments in the Global Organ Transplant Diagnostics Market

• In April 2023, bioMerieux S.A. and Oxford Nanopore entered into a strategic partnership agreement to develop innovative infectious disease diagnostics, which would also lead to the development of infectious disease tests used during transplantation.
• In April 2023, CareDx and Miromatrix announced an exclusive partnership to advance research using bioengineered organs for human transplantation.
• In December 2022, GenDx partnered with Azure Biosystems, a leading provider of innovative bioanalytical solutions for protein and genomic research, to demonstrate the compatibility of the Azure Cielo 6 qPCR System with the GenDx KMRtype and KMRtrack kits.
• In November 2022, Bio-Rad Laboratories and NuProbe USA signed a licensing agreement for digital PCR assay development. The technology would advance Bio-Rad's portfolio.
• In October 2022, Eurobio Scientific finalized the purchase of a 100% stake in Genome Diagnostics BV (GenDx) in a deal valued at $132.3 million.
• In September 2022, BioMAdvanced Diagnostics announced fundraising of $1.3 million. The fundraising would allow BioMAdvanced Diagnostics to finalize the design of its first products and to start two clinical studies, one on the rejection of kidney transplants and the other on the lung.
• In September 2022, BioMAdvanced Diagnostics announced the launch of Design Freeze of its IVD test for transplant kidney rejection.
• In September 2022, GenDx announced that it signed a non-exclusive service agreement with Oxford Nanopore Technologies (Oxford Nanopore) to bring its new NGS-Turbo product to the transplant market for high-resolution HLA typing.

Demand - Drivers and Limitations

Following are the drivers for the Global Organ Transplant Diagnostics market:

• Rise in the Incidence of Chronic Diseases Leading to Organ Failure Increases the Use of Transplant Diagnostics
• Increase in the Adoption of Stem Cell Therapy and Incidences of Leukemia Leading to an Upsurge in Demand for Transplant Diagnostics Tests
• Advantages of Developing Advanced Molecular and Genomic Technologies in the Transplant Diagnostics Tests
• Presence of Favorable Regulatory Scenario Including Reimbursement Schemes

The market is expected to face some limitations as well due to the following challenges:

• Increased Gap in Organ Donation and Organ Transplant Demand, which Hinders the Growth of the Organ Transplant Diagnostics Market
• High Cost of Investment for Transplant Diagnostics Tests

How can this report add value to an organization?

Offerings: The offerings segment helps the reader understand the different manufacturers and service providers available in the market for organ transplant diagnostics. Moreover, the study provides the reader with a detailed understanding of transplant types and applications.

Growth/Marketing Strategy: The global organ transplant diagnostics market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been synergistic activities such as partnerships, collaborations, expansions, and funding activities. For instance, in April 2023, bioMerieux S.A. and Oxford Nanopore entered into a strategic partnership agreement to develop innovative infectious disease diagnostics, which will also lead to the development of infectious disease tests used during transplantation.

Competitive Strategy: The key players in the global organ transplant diagnostics market analyzed and profiled in the study involve established and emerging players that offer different products and services for organ transplant diagnostics. Moreover, a detailed competitive benchmarking of the players operating in the global organ transplant diagnostics market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, and mergers and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled

Manufacturers

• Abbott Laboratories
• BAG Group GmbH
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Eurobio Scientific
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Immucor, Inc.
• Omixon Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Service Providers

• ARUP Laboratories
• CareDx, Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated

Table of Contents

1 Product Definition

• 1.1 Inclusion and Exclusion Criteria

2 Market Scope

• 2.1 Scope of Work
• 2.2 Key Questions Answered in the Report:

3 Research Methodology

• 3.1 Global Organ Transplant Diagnostics Market: Research Methodology
• 3.2 Data Sources
  • 3.2.1 Primary Data Sources
  • 3.2.2 Secondary Data Sources
• 3.3 Market Estimation Model
• 3.4 Criteria for Company Profiling

4 Global Organ Transplant Diagnostics Market: Overview

• 4.1 Current Market Scenario
  • 4.1.1 For Researchers
  • 4.1.2 For Diagnostics
• 4.2 Market Footprint
• 4.3 COVID-19 Impact on Market
  • 4.3.1 Impact on Operations
  • 4.3.2 COVID-19 Impact: Current Scenario of Market
  • 4.3.3 Pre- and Post-COVID-19 Impact Assessment
    • 4.3.3.1 Pre-COVID-19 Phase
    • 4.3.3.2 Post-COVID-19 Phase

5 Global Organ Transplant Diagnostics Market: Industry Analysis

• 5.1 Overview
• 5.2 Legal Requirements and Regulatory Frameworks in the U.S.
  • 5.2.1 U.S. FDA Regulation
  • 5.2.2 CMS Regulation
• 5.3 Legal Requirements and Framework in Europe
• 5.4 Legal Requirements and Framework in Asia-Pacific
  • 5.4.1 China
  • 5.4.2 Japan
• 5.5 Reimbursement Scenario
• 5.6 Patent Analysis
  • 5.6.1 Patent Filing Trend (by Country)
  • 5.6.2 Patent Filing Trend (by Year)

6 Global Organ Transplant Diagnostics Market: Market Dynamics

• 6.1 Impact Analysis
• 6.2 Market Drivers
  • 6.2.1 Rise in Incidence of Chronic Diseases Leading to Organ Failure Increases the Use of Transplant Diagnostics
  • 6.2.2 Increase in Adoption of Stem Cell Therapy and Incidences of Leukemia Leading to an Upsurge in Demand for Transplant Diagnostics Tests
  • 6.2.3 Presence of Favorable Regulatory Scenarios including Reimbursement Schemes for Some Organ Transplant Diagnostics
  • 6.2.4 Advantages of Developing Advanced Molecular and Genomic Technologies in Transplant Diagnostics Tests
• 6.3 Market Restraints
  • 6.3.1 Increased Gap in Organ Donation and Organ Transplant Demand Hinders the Growth of Organ Transplant Diagnostics Market
  • 6.3.2 High Cost of Investment for Transplant Diagnostics Tests Acts as a Barrier to Growth of the Market
• 6.4 Market Opportunities
  • 6.4.1 Development of Non-Invasive Techniques for Monitoring Transplant Recipients using NGS
  • 6.4.2 Advancements in Human Leukocyte Antigen (HLA) Typing Tests for Organ Transplant

7 Competitive Insights

• 7.1 Overview
• 7.2 Key Strategies and Development
  • 7.2.1 Synergistic Activities
  • 7.2.2 Product and Service Launches
  • 7.2.3 Product Approvals
  • 7.2.4 Acquisitions and Mergers
  • 7.2.5 Regulatory Accreditions
• 7.3 Market Share Analysis 2021 vs. 2022
• 7.4 Growth-Share Analysis
  • 7.4.1 By Company

8 Global Organ Transplant Diagnostics Market: (by Offering)

• 8.1 Overview
• 8.2 Products
  • 8.2.1 Kits and Assays
  • 8.2.2 Consumables
• 8.3 Services

9 Global Organ Transplant Diagnostics Market: (by Transplant Type)

• 9.1 Overview
• 9.2 Solid Organ Transplant
  • 9.2.1 Kidney
  • 9.2.2 Liver
  • 9.2.3 Lung
  • 9.2.4 Pancreas
  • 9.2.5 Other Organs Transplant
• 9.3 Stem Cell Transplant

10 Global Organ Transplant Diagnostics Market: (by Application)

• 10.1 Overview
• 10.2 Diagnostics
  • 10.2.1 Donor Testing
    • 10.2.1.1 Pre-Transplantation Testing
      • 10.2.1.1.1 Histocompatibility Testing
      • 10.2.1.1.2 Blood Profiling Testing
      • 10.2.1.1.3 Other Testing
    • 10.2.1.2 Post-Transplantation Testing
      • 10.2.1.2.1 Post-Infection Testing
      • 10.2.1.2.2 Risk of Disorder Testing
      • 10.2.1.2.3 Other Testing
  • 10.2.2 Recipient Testing
    • 10.2.2.1 Pre-Transplantation Testing
      • 10.2.2.1.1 Histocompatibility Testing
      • 10.2.2.1.2 Blood Profiling Testing
      • 10.2.2.1.3 Other Testing
    • 10.2.2.2 Post-Transplantation Testing
      • 10.2.2.2.1 Post-Infection Testing
      • 10.2.2.2.2 Risk of Disorder Testing
      • 10.2.2.2.3 Other Testing
• 10.3 Translational Research

11 Global Organ Transplant Diagnostics Market: (by Technology)

• 11.1 Overview
• 11.2 Molecular Technologies
  • 11.2.1 PCR
  • 11.2.2 Sanger Sequencing
  • 11.2.3 Next-Generation Sequencing (NGS)
  • 11.2.4 Other Molecular Technologies
• 11.3 Non-Molecular Technologies
  • 11.3.1 Serology
  • 11.3.2 Flow Cytometry
• 11.4 Other Technologies

12 Global Organ Transplant Diagnostics Market: (by End User)

• 12.1 Overview
• 12.2 Hospitals and Transplant Centers
• 12.3 Academic and Research Institutions
• 12.4 Reference Laboratories
• 12.5 Other End Users

13 Region

• 13.1 North America
  • 13.1.1 North America Organ Transplant Test Volume, by Transplant Type
  • 13.1.2 Market Sizing and Forecast
    • 13.1.2.1 North America Organ Transplant Diagnostics Market (by Country)
      • 13.1.2.1.1 U.S.
      • 13.1.2.1.2 Canada
• 13.2 Europe
  • 13.2.1 Europe Organ Transplant Test Volume, by Transplant Type
  • 13.2.2 Market Sizing and Forecast
    • 13.2.2.1 Europe Organ Transplant Diagnostics Market (by Country)
      • 13.2.2.1.1 France
      • 13.2.2.1.2 Spain
      • 13.2.2.1.3 U.K.
      • 13.2.2.1.4 Italy
      • 13.2.2.1.5 Germany
      • 13.2.2.1.6 Switzerland
      • 13.2.2.1.7 Rest-of-Europe
• 13.3 Asia-Pacific
  • 13.3.1 Asia-Pacific Organ Transplant Test Volume, by Transplant Type
  • 13.3.2 Market Sizing and Forecast
    • 13.3.2.1 Asia-Pacific Organ Transplant Diagnostics Market (by Country)
      • 13.3.2.1.1 China
      • 13.3.2.1.2 India
      • 13.3.2.1.3 South Korea
      • 13.3.2.1.4 Japan
      • 13.3.2.1.5 Australia
      • 13.3.2.1.6 Singapore
      • 13.3.2.1.7 Rest-of-Asia-Pacific
• 13.4 Latin America
  • 13.4.1 Latin America Organ Transplant Test Volume, by Transplant Type
  • 13.4.2 Market Sizing and Forecast
    • 13.4.2.1 Latin America Organ Transplant Diagnostics Market (by Country)
      • 13.4.2.1.1 Brazil
      • 13.4.2.1.2 Mexico
      • 13.4.2.1.3 Rest-of-Latin America
• 13.5 Rest-of-the-World
  • 13.5.1 Rest-of-the-World Organ Transplant Test Volume, by Transplant Type
  • 13.5.2 Market Sizing and Forecast

14 Company Profiles

• 14.1 Overview
• 14.2 Manufacturers
  • 14.2.1 Abbott Laboratories
    • 14.2.1.1 Company Overview
    • 14.2.1.2 Role of Abbott Laboratories in the Organ Transplant Diagnostics Market
    • 14.2.1.3 Product Portfolio
    • 14.2.1.4 Financials
    • 14.2.1.5 Analyst Perception
  • 14.2.2 BAG Group GmbH
    • 14.2.2.1 Company Overview
    • 14.2.2.2 Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
    • 14.2.2.3 Product Portfolio
    • 14.2.2.4 Analyst Perception
  • 14.2.3 bioMerieux S.A.
    • 14.2.3.1 Company Overview
    • 14.2.3.2 Role of bioMerieux S.A. in the Organ Transplant Diagnostics Market
    • 14.2.3.3 Product Portfolio
    • 14.2.3.4 Financials
    • 14.2.3.5 Recent Developments
    • 14.2.3.6 Analyst Perception
  • 14.2.4 Bio-Rad Laboratories, Inc.
    • 14.2.4.1 Company Overview
    • 14.2.4.2 Role of Bio-Rad Laboratories, Inc. in the Organ Transplant Diagnostics Market
    • 14.2.4.3 Product Portfolio
    • 14.2.4.4 Financials
    • 14.2.4.5 Recent Developments
    • 14.2.4.6 Analyst Perception
  • 14.2.5 Eurobio Scientific (Genome Diagnostics B.V.)
    • 14.2.5.1 Company Overview
    • 14.2.5.2 Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
    • 14.2.5.3 Product Portfolio
    • 14.2.5.4 Analyst Perception
  • 14.2.6 F. Hoffmann-La Roche Ltd.
    • 14.2.6.1 Company Overview
    • 14.2.6.2 Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
    • 14.2.6.3 Product Portfolio
    • 14.2.6.4 Financials
    • 14.2.6.5 Recent Developments
    • 14.2.6.6 Analyst Perception
  • 14.2.7 Illumina, Inc.
    • 14.2.7.1 Company Overview
    • 14.2.7.2 Role of Illumina, Inc. in the Organ Transplant Diagnostics Market
    • 14.2.7.3 Product Portfolio
    • 14.2.7.4 Financials
    • 14.2.7.5 Analyst Perception
  • 14.2.8 Immucor, Inc.
    • 14.2.8.1 Company Overview
    • 14.2.8.2 Role of Immucor, Inc. in the Organ Transplant Diagnostics Market
    • 14.2.8.3 Product Portfolio
    • 14.2.8.4 Analyst Perception
  • 14.2.9 Omixon Inc.
    • 14.2.9.1 Company Overview
    • 14.2.9.2 Role of Omixon Inc. in the Organ Transplant Diagnostics Market
    • 14.2.9.3 Product Portfolio
    • 14.2.9.4 Analyst Perception
  • 14.2.10 QIAGEN N.V.
    • 14.2.10.1 Company Overview
    • 14.2.10.2 Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
    • 14.2.10.3 Product Portfolio
    • 14.2.10.4 Financials
    • 14.2.10.5 Recent Developments
    • 14.2.10.6 Analyst Perception
  • 14.2.11 Thermo Fisher Scientific Inc.
    • 14.2.11.1 Company Overview
    • 14.2.11.2 Role of Thermo Fisher Scientific Inc. in the Organ Transplant Diagnostics Market
    • 14.2.11.3 Product Portfolio
    • 14.2.11.4 Financials
    • 14.2.11.5 Recent Developments
    • 14.2.11.6 Analyst Perception
• 14.3 Service Providers
  • 14.3.1 ARUP Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Role of ARUP Laboratories in the Organ Transplant Diagnostics Market
    • 14.3.1.3 Product Portfolio
    • 14.3.1.4 Analyst Perception
  • 14.3.2 CareDx, Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Role of CareDx, Inc. in the Organ Transplant Diagnostics Market
    • 14.3.2.3 Product Portfolio
    • 14.3.2.4 Financials
    • 14.3.2.5 Recent Developments
    • 14.3.2.6 Analyst Perception
  • 14.3.3 Laboratory Corporation of America Holdings
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Role of Laboratory Corporation of America Holdings in the Organ Transplant Diagnostics Market
    • 14.3.3.3 Product Portfolio
    • 14.3.3.4 Financials
    • 14.3.3.5 Analyst Perception
  • 14.3.4 Quest Diagnostics Incorporated
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Role of Quest Diagnostics Incorporated in the Organ Transplant Diagnostics Market
    • 14.3.4.3 Product Portfolio
    • 14.3.4.4 Financials
    • 14.3.4.5 Analyst Perception